Aspirin but not meloxicam attenuates early atherosclerosis in apolipoprotein E knockout mice

Israel Medical Association Journal

Volumn 16, Issue 4, 2014, Pages 233-238

  Kraus, Sarah ^a,d   Naumov, Inna ^a   Shapira, Shiran ^a   Kazanov, Dina ^a   Aroch, Ilan ^a   Afek, Arnon ^b   Eisenberg, Oded ^c   George, Jacob ^c   Arber, Nadir ^a,d   Finkelstein, Ariel ^a,d  

^a TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

^b SHEBA MEDICAL CENTER   (Israel)

^c HEBREW UNIVERSITY   (Israel)

^d TEL AVIV UNIVERSITY   (Israel)

Author keywords

Apolipoprotein E; Aspirin; Atherosclerosis; Cyclooxygenase (COX) 2 inhibitor; Mouse model

Indexed keywords

ACETYLSALICYLIC ACID; APOLIPOPROTEIN E; COLLAGEN; MELOXICAM;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; CONTROLLED STUDY; HISTOCHEMISTRY; LOW DRUG DOSE; MALE; MICROSCOPE; MORPHOMETRICS; MOUSE; NONHUMAN; STAINING; THROMBOSIS;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; APOLIPOPROTEINS E; ASPIRIN; ATHEROSCLEROSIS; CYCLOOXYGENASE 2 INHIBITORS; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; PLAQUE, ATHEROSCLEROTIC; THIAZINES; THIAZOLES;

EID: 84898440429     PISSN: 15651088     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 2005; 352: 1685-95.
2. Mizuno Y, Jacob RF, Mason RP. Inflammation and the development of atherosclerosis - effects of lipid-lowering therapy. J Atheroscler Thromb 2011; 18: 351-8.
3. Qin N, Zhang SP, Reitz TL, Mei JM, Flores CM. Cloning, expression, and functional characterization of human cyclooxygenase-1 splicing variants: evidence for intron 1 retention. J Pharmacol Exp Ther 2005; 315: 1298-305.
4. Gatti D, Adami S. Coxibs: a significant therapeutic opportunity. Acta Biomed 2010; 81: 217-24.
5. Baron JA, Sandler RS, Bresalier RS, et al. Cardiovascular events associated with rofecoxib: final analysis of the APPROVe trial. Lancet 2008; 372: 1756-64.
6. Arber N, Eagle CJ, Spicak J, et al.; PreSAP trial investigators. Celecoxib for the prevention of colorectal adenomatous polyps. N Engl J Med 2006; 355: 885-95.
7. Bertagnolli MM, Eagle CJ, Zauber AG, et al.; APC study investigators. Celecoxib for the prevention of sporadic colorectal adenomas. N Engl J Med 2006; 355: 873-4.
8. Meyrelles SS, Peotta VA, Pereira TM, Vasquez EC. Endothelial dysfunction in the apolipoprotein E-deficient mouse: insights into the influence of diet, gender and aging. Lipids Health Dis 2011; 10: 211-20.
9. Meir KS, Leitersdorf E. Atherosclerosis in the apolipoprotein-E-deficient mouse: a decade of progress. Arterioscler Thromb Vasc Biol 2004; 24: 1006-14.
10. Moghadasian MH, McManus BM, Nguyen LB, et al. Pathophysiology of apolipoprotein E deficiency in mice: relevance to apo E-related disorders in humans. FASEB J 2001; 15: 2623-30.
11. Niza M, Felix N, Vilela CL, Peleteiro MC, Ferreira AJ. Cutaneous and ocular adverse reactions in a dog following meloxicam administration. Vet Dermatol 2007; 18: 45-9.
12. Patrono C, Garcia Rodriguez LA, Landolfi R, Baigent C. Low-dose aspirin for the prevention of atherothrombosis. N Engl J Med 2005; 353: 2373-83.
13. Patrono C, Coller B, FitzGerald GA, Hirsh J, Roth G. Platelet-active drugs: the relationships among dose, effectiveness, and side effects: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126: 234-64S.
14. Del Tacca M, Colucci R, Fornai M, Blandizzi C. Efficacy and tolerability of meloxicam, a COX-2 preferential nonsteroidal anti-inflammatory drug. Clin Drug Invest 2002; 22: 799-818.
15. Mcllhatton MA, Tyler J, Kerepesi LA, et al. Aspirin and low-dose nitric oxide donating aspirin increase life span in a Lynch syndrome mouse model. Cancer Prev Res (Phila) 2011; 4: 684-93.
16. George J, Afek A, Abashidze A, et al. Transfer of endothelial progenitor and bone marrow cells influences atherosclerotic plaque size and composition in apolipoprotein E knockout mice. Arterioscler Thromb Vasc Biol 2005; 25: 2636-41.
17. Burleigh ME, Babaev VR, Oates JA, et al. Cyclooxygenase-2 promotes early atherosclerotic lesion formation in LDL receptor-deficient mice. Circulation 2002; 105: 1816-23.
18. Cleland JGF. Preventing atherosclerotic events with aspirin. Br Med J 2002; 342: 71-86.
19. Tillman C, Yuemang Y, Liun XT, Domenico P. Stabilization of advanced atherosclerosis in low-density lipoprotein receptor-deficient mice by aspirin. Atherosclerosis 2006; 184: 8-14.
20. Yamamoto Y, Yamashita T, Kitagawa F, Sakamoto K, Giddings JC, Yamamoto J. The effect of long term aspirin administration on the progress of atherosclerosis in apoE-/- LDLR-/- double knockout mouse. Thromb Res 2010; 125: 246-52.
21. Weismann SM, Graham DY. Evaluation of the benefits and risks of low-dose aspirin in the secondary prevention of cardiovascular and cerebrovascular events. Arch Intern Med 2002; 162: 2197-202.
22. Shen L, Matsunami Y, Quan N, Kobayashi K, Matsuura E, Oguma K. In vivo oxidation, platelet activation and simultaneous occurrence of natural immunity in atherosclerosis-prone mice. IMAJ 2011; 13: 278-83.
23. Clarke RJ, Mayo G, Price P, FitzGerald GA. Suppression of thromboxane A2 but not of systemic prostacyclin by controlled-release aspirin. N Engl J Med 1991; 325: 1137-41.
24. Fransen P, Van Assche T, Guns PJ, et al. Endothelial function in aorta segments of apolipoprotein E-deficient mice before development of atherosclerotic lesions. Pflugers Arch 2008; 455: 811-18.
25. Crauwels HM, Van Hove CE, Holvoet P, Herman AG, Bult H. Plaque-associated endothelial dysfunction in apolipoprotein E-deficient mice on a regular diet. Effect of human apolipoprotein AI. Cardiovasc Res 2003; 59: 189-99.